Startups
Datar Cancer Genetics Europe (DCGE) offers highly accurate diagnostic solutions for cancer patients. Its main focus is on patients in advanced cancer stages and with tumours difficult to treat. The solutions offered can also serve as support for treatments which have achieved little to no success so far.
The in-house, fully equipped, state-of-the-art medical laboratory is ISO 15189, CAP and CLIA accredited/certified, thus meeting international standards. The DCG team consists mainly of scientists, physicians and bioinformatic specialists. The bioinformatics team has developed an algorithm that combines the results of the extensive tests and translates them into clinically relevant information.
With DCGE, Datar Cancer Genetics Limited (DCGL) has a permanent base in Germany to market and sell their diagnostic solutions and to find new research cooperations. DCGE is responsible for most of Europe.
The in-house, fully equipped, state-of-the-art medical laboratory is ISO 15189, CAP and CLIA accredited/certified, thus meeting international standards. The DCG team consists mainly of scientists, physicians and bioinformatic specialists. The bioinformatics team has developed an algorithm that combines the results of the extensive tests and translates them into clinically relevant information.
With DCGE, Datar Cancer Genetics Limited (DCGL) has a permanent base in Germany to market and sell their diagnostic solutions and to find new research cooperations. DCGE is responsible for most of Europe.
Overview
Location
Germany, Bavaria, Forst
Employees
1-10
Founded date
2019
FAQ about Datar Cancer Genetics Europe GmbH
When was Datar Cancer Genetics Europe GmbH founded?
Datar Cancer Genetics Europe GmbH was founded in 2019.
Is Datar Cancer Genetics Europe GmbH still active?
Yes, Datar Cancer Genetics Europe GmbH is active; its latest activity on Parsers VC dates from Nov 20, 2021.